Clinical Trial

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as the care most people get for Primary Central Nervous System Lymphoma (PCNSL).
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2023-08-11; most recent amendment 2026-04-13.
Status change: Not Yet Recruiting → Recruiting 2023-12-11
Trial Details
NCT Number NCT05998642
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Janssen Inc.
Conditions Non-hodgkin Lymphoma
Enrollment 30 participants
Start Date 2024-02-13
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-14